Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (219)	5/2/2005 6:15:07 AM
From: nigel bates	Read Replies (1) \| Respond to of 684

These folks don't have any incentive to "bleed" the company... Inertia, and the triumph of hope over experience ? Certainly, the CEO's immediate reaction to failure in the clinic doesn't inspire confidence on that score - ...John McLaughlin, president and chief executive officer of Corgentech. "We are fortunate to have a deep pipeline of products to choose from and have the ability to generate new product candidates very rapidly. Corgentech's NF-kappaB (NFkB) Decoy, which was generated in just five months, will enter the clinic shortly for eczema, and we plan to select our next clinical candidate in the second half of this year."... If they were smart, there ought to be several interesting-but-cash-starved pipelines at a later stage of development they could hook up with to the benefit of all concerned, but I suspect the 'not-invented-here' syndrome will win out.

To: fred hayes who wrote (219)	6/9/2005 3:32:31 PM
From: tuck	Respond to of 684

FWIW, CGTK still way below cash value, and Biotechnology Value Fund just a few days ago took a 5% position. There is a CGTK thread that discussed the science a bit. Cheers, Tuck